secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001140361-25-041286
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech reports positive translational data for PDS0101 and PDS01ADC at SITC 2025
--------------------------------------------------------------------------------

- Translational study of PDS0101 combo in 50 patients shows multiple serum biomarkers predict clinical benefit accurately.
- PDS01ADC monotherapy increases NK cells with tumor-killing phenotypes and decreases poor-response NK cells in advanced solid tumors.
- PDS01ADC increases self-replicating stem-like memory T cells (CD8 and CD4) associated with disease stabilization in 28 patients.
- Data selected among top 150 abstracts at SITC; presented under NCI CRADA collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125041286/0001140361-25-041286-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125041286/ef20058659_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-041286

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer